The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia

There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show limited benefit f...

Full description

Bibliographic Details
Main Authors: Jack Cotter, Jennifer H. Barnett, Kiri Granger
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fpsyt.2019.00648/full